当前位置： SCI文献检索 > BREAST CANCER RESEARCH AND TREATMENT期刊下所有文献 > Syndecan-1 facilitates breast cancer metastasis to the brain.

Syndecan-1 facilitates breast cancer metastasis to the brain.

Abstract：

PURPOSE:Although survival rates for patients with localized breast cancer have increased, patients with metastatic breast cancer still have poor prognosis. Understanding key factors involved in promoting breast cancer metastasis is imperative for better treatments. In this study, we investigated the role of syndecan-1 (Sdc1) in breast cancer metastasis. METHODS:To assess the role of Sdc1 in breast cancer metastasis, we silenced Sdc1 expression in the triple-negative breast cancer human MDA-MB-231 cell line and overexpressed it in the mouse mammary carcinoma 4T1 cell line. Intracardiac injections were performed in an experimental mouse metastasis model using both cell lines. In vitro transwell blood-brain barrier (BBB) and brain section adhesion assays were utilized to specifically investigate how Sdc1 facilitates brain metastasis. A cytokine array was performed to evaluate differences in the breast cancer cell secretome when Sdc1 is silenced. RESULTS:Silencing expression of Sdc1 in breast cancer cells significantly reduced metastasis to the brain. Conversely, overexpression of Sdc1 increased metastasis to the brain. We found that silencing of Sdc1 expression had no effect on attachment of breast cancer cells to brain endothelial cells or astrocytes, but migration across the BBB was reduced as well as adhesion to the perivascular regions of the brain. Loss of Sdc1 also led to changes in breast cancer cell-secreted cytokines/chemokines, which may influence the BBB. CONCLUSIONS:Taken together, our study demonstrates a role for Sdc1 in promoting breast cancer metastasis to the brain. These findings suggest that Sdc1 supports breast cancer cell migration across the BBB through regulation of cytokines, which may modulate the BBB. Further elucidating this mechanism will allow for the development of therapeutic strategies to combat brain metastasis.

journal_name

Breast Cancer Res Treat

journal_title

Breast cancer research and treatment

authors

Sayyad MR,Puchalapalli M,Vergara NG,Wangensteen SM,Moore M,Mu L,Edwards C,Anderson A,Kall S,Sullivan M,Dozmorov M,Singh J,Idowu MO,Koblinski JE

doi

10.1007/s10549-019-05347-0

subject

Has Abstract

pub_date

2019-11-01 00:00:00

pages

35-49

issue

1

eissn

0167-6806

issn

1573-7217

pii

10.1007/s10549-019-05347-0

journal_volume

178

pub_type

杂志文章

相关文献

BREAST CANCER RESEARCH AND TREATMENT文献大全
  • Associations between mammographic density and serum and dietary cholesterol.

    abstract：:Although high mammographic density is a risk factor for postmenopausal breast cancer, its etiology remains unclear. We examined whether serum and dietary cholesterol, which increase breast cancer risk and are involved in endogenous estrogen formation, were associated with increased mammographic density. We conducted a...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,多中心研究,随机对照试验

    doi：10.1007/s10549-010-0927-7

    authors： Tamburrini AL,Woolcott CG,Boyd NF,Yaffe MJ,Terry T,Yasui Y,Jones CA,Patten SB,Courneya KS,Friedenreich CM

    更新日期：2011-01-01 00:00:00

  • Drug dosage intensity--a panel discussion.

    abstract：:There is now widespread interest in the subject of drug dose intensity in cancer treatment. Recent retrospective analyses have shown a clear-cut benefit for those patients receiving either the intended drug dosage in a particular regimen or the highest dosage achievable through an escalation scheme. In this discussion...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/BF01807361

    authors： McGuire WL,Goldie J,Hryniuk W,Tormey DC

    更新日期：1987-01-01 00:00:00

  • BRCA testing and outcomes in women with breast cancer.

    abstract：MAIN PURPOSE:Germline BRCA mutations (BRCAm) strongly influence the risk of developing breast cancer. This study aimed to understand the role of BRCAm testing in affected individuals and to assess its impact on the outcome of BRCAm carriers compared to non-carriers (BRCAwt) with breast cancer. RESEARCH QUESTION:The re...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-020-06038-x

    authors： Stenehjem DD,Telford C,Unni SK,Bauer H,Sainski A,Deka R,Schauerhamer MB,Ye X,Tak CR,Ma J,Dalvi TB,Gutierrez L,Kaye JA,Tyczynski JE,Brixner DI,Biskupiak JE

    更新日期：2021-01-03 00:00:00

  • Genomic predictors of response to doxorubicin versus docetaxel in primary breast cancer.

    abstract：UNLABELLED:Taxanes and anthracyclines improve the outcome of early breast cancer, although the benefit is limited to a small proportion of patients and are toxic. We prospectively looked for predictors of response to these drugs. EXPERIMENTAL DESIGN:Four cycles of doxorubicin (75 mg/m²) or docetaxel (100 mg/m²) were c...

    journal_title：Breast cancer research and treatment

    pub_type： 临床试验,杂志文章

    doi：10.1007/s10549-011-1461-y

    authors： Martin M,Romero A,Cheang MC,López García-Asenjo JA,García-Saenz JA,Oliva B,Román JM,He X,Casado A,de la Torre J,Furio V,Puente J,Caldés T,Vidart JA,Lopez-Tarruella S,Diaz-Rubio E,Perou CM

    更新日期：2011-07-01 00:00:00

  • Higher stromal expression of transforming growth factor-beta type II receptors is associated with poorer prognosis breast tumors.

    abstract：:Transforming growth factor-beta (TGFB) is a potent inhibitor of normal epithelial cell proliferation, and may be one of the regulatory factors that are perturbed during tumor development. While many tumor cell lines no longer respond to the inhibitory effects of TGFB due to a reduction or absence of the type II recept...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1023/a:1023918026437

    authors： Barlow J,Yandell D,Weaver D,Casey T,Plaut K

    更新日期：2003-05-01 00:00:00

  • A phase II trial of cyclophosphamide, epirubicin and vinorelbine in the treatment of advanced breast cancer.

    abstract：BACKGROUND:Vinorelbine (Navelbin; N) has proven to be active in patients with advanced breast cancer (ABC) and cyclophosphamide (C) and epirubicin (Epiadriamycin: E) are still among the main cytostatic agents against this tumor. On this basis was carried out a study to determine the activity and toxicity of the combina...

    journal_title：Breast cancer research and treatment

    pub_type： 临床试验,杂志文章,多中心研究

    doi：10.1023/a:1006477109230

    authors： Esteban E,de Sande G,Puertas J,Fra J,Palacio I,Vieitez JM,Fernández JL,Muñiz I,Modollel A,Carrasco J,Sala M,Lacave AJ

    更新日期：2000-07-01 00:00:00

  • Prognostic value of histopathological DCIS features in a large-scale international interrater reliability study.

    abstract：PURPOSE:For optimal management of ductal carcinoma in situ (DCIS), reproducible histopathological assessment is essential to distinguish low-risk from high-risk DCIS. Therefore, we analyzed interrater reliability of histopathological DCIS features and assessed their associations with subsequent ipsilateral invasive bre...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-020-05816-x

    authors： Groen EJ,Hudecek J,Mulder L,van Seijen M,Almekinders MM,Alexov S,Kovács A,Ryska A,Varga Z,Andreu Navarro FJ,Bianchi S,Vreuls W,Balslev E,Boot MV,Kulka J,Chmielik E,Barbé E,de Rooij MJ,Vos W,Farkas A,Leeuwis-Fedoro

    更新日期：2020-10-01 00:00:00

  • Cyclin-dependent kinase 4 and 6 inhibitors in hormone receptor-positive, human epidermal growth factor receptor-2 negative advanced breast cancer: a meta-analysis of randomized clinical trials.

    abstract：BACKGROUND:Breakthrough progress has been made in Cyclin-Dependent kinase 4 and 6 (CDK4/6) inhibitors when combined with endocrine therapy (ET) for hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC). Though significant improvements of progression-free survival (PFS) for CDK4/6 inhibitor...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,meta分析,评审

    doi：10.1007/s10549-020-05528-2

    authors： Li J,Fu F,Yu L,Huang M,Lin Y,Mei Q,Lv J,Wang C

    更新日期：2020-02-01 00:00:00

  • Four-day infusion of fluorouracil plus vinorelbine as salvage treatment of heavily pretreated metastatic breast cancer.

    abstract：AIMS:Anthracyclines-taxanes containing regimens are widely used for breast cancer treatment both in neoadjuvant-adjuvant setting and in metastatic disease. Recently high-dose chemotherapy (HDC) with autologous stem cell support has been introduced as adjuvant treatment for high-risk primary breast cancer and for select...

    journal_title：Breast cancer research and treatment

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：10.1023/a:1006462023110

    authors： Zambelli A,Robustelli della Cuna FS,Ponchio L,Ucci G,Da Prada GA,Robustelli della Cuna G

    更新日期：2000-06-01 00:00:00

  • Overexpression of p53 is correlated with poor outcome in premenopausal women with breast cancer treated with tamoxifen after chemotherapy.

    abstract：:The aim of this study was to evaluate the difference in outcomes based on p53 overexpression of patients with breast cancer who received adjuvant therapy following local treatment for invasive ductal carcinoma, not otherwise specified. We analyzed data from 4,683 patients with cancer enrolled in two institutions betwe...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,多中心研究

    doi：10.1007/s10549-009-0560-5

    authors： Kim HS,Yom CK,Kim HJ,Lee JW,Sohn JH,Kim JH,Park YL,Ahn SH

    更新日期：2010-06-01 00:00:00

  • The impact of sharing results of a randomized breast cancer clinical trial with study participants.

    abstract：BACKGROUND:There has been growing interest in providing clinical trial participants with study results yet only limited information exists regarding the process and impact of sharing results. We sought to evaluate patient perceptions of how results had been shared from a large randomized cooperative group trial, and th...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,随机对照试验

    doi：10.1007/s10549-008-0057-7

    authors： Partridge AH,Wolff AC,Marcom PK,Kaufman PA,Zhang L,Gelman R,Moore C,Lake D,Fleming GF,Rugo HS,Atkins J,Sampson E,Collyar D,Winer EP

    更新日期：2009-05-01 00:00:00

  • Chlorpheniramine inhibits the synthesis of ornithine decarboxylase and the proliferation of human breast cancer cell lines.

    abstract：:Proliferation of both mouse and human breast cancer cells was inhibited by chlorpheniramine (CPA) in a dose-response manner. At the beginning of the exponential phase of growth (two days after seeding), 250 microM CPA was able to reduce cell proliferation by 75% (in Ehrlich cell cultures) and 30% (in MCF-7 cultures). ...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/BF00668208

    authors： Medina MA,García de Veas R,Morata P,Lozano J,Sánchez-Jiménez F

    更新日期：1995-08-01 00:00:00

  • Fruits, vegetables, and micronutrient intake in relation to breast cancer survival.

    abstract：OBJECTIVE:To determine whether fruit, vegetable, and micronutrient intake 1 year prior to breast cancer diagnosis is associated with a reduction in the subsequent risk of all-cause or breast cancer-specific mortality. METHODS:Follow-up data from 1,235 invasive breast cancer cases age 25-98 years from the Long Island B...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-005-9150-3

    authors： Fink BN,Gaudet MM,Britton JA,Abrahamson PE,Teitelbaum SL,Jacobson J,Bell P,Thomas JA,Kabat GC,Neugut AI,Gammon MD

    更新日期：2006-07-01 00:00:00

  • Dietary intake of soy and cruciferous vegetables and treatment-related symptoms in Chinese-American and non-Hispanic White breast cancer survivors.

    abstract：PURPOSE:This project was undertaken to examine the association between dietary intake of soy or cruciferous vegetables and breast cancer treatment-related symptoms among Chinese-American (CA) and Non-Hispanic White (NHW) breast cancer survivors. METHODS:This cross-sectional study included 192 CA and 173 NHW female bre...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-017-4578-9

    authors： Nomura SJO,Hwang YT,Gomez SL,Fung TT,Yeh SL,Dash C,Allen L,Philips S,Hilakivi-Clarke L,Zheng YL,Wang JH

    更新日期：2018-04-01 00:00:00

  • Comparison of resection margin status after single or double radiopaque marker insertion for tumor localization in breast cancer patients receiving neoadjuvant chemotherapy.

    abstract：PURPOSE:Insertion of radiopaque markers is helpful for tumor localization in patients receiving neoadjuvant chemotherapy (NAC) followed by breast-conserving surgery (BCS). The aim of this retrospective study was to investigate the pathologic margin status in patients with single or double marker insertion. METHODS:We ...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-020-05907-9

    authors： Cha C,Lee J,Kim D,Park S,Bae SJ,Eun NL,Ahn SG,Son EJ,Jeong J

    更新日期：2020-12-01 00:00:00

  • A systematic review of breast cancer incidence risk prediction models with meta-analysis of their performance.

    abstract：:A risk prediction model is a statistical tool for estimating the probability that a currently healthy individual with specific risk factors will develop a condition in the future such as breast cancer. Reliably accurate prediction models can inform future disease burdens, health policies and individual decisions. Brea...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,meta分析,评审

    doi：10.1007/s10549-011-1818-2

    authors： Meads C,Ahmed I,Riley RD

    更新日期：2012-04-01 00:00:00

  • Evidence for biological effects of metformin in operable breast cancer: a pre-operative, window-of-opportunity, randomized trial.

    abstract：:Metformin may reduce the incidence of breast cancer and enhance response to neoadjuvant chemotherapy in diabetic women. This trial examined the effects of metformin on Ki67 and gene expression in primary breast cancer. Non-diabetic women with operable invasive breast cancer received pre-operative metformin. A pilot co...

    journal_title：Breast cancer research and treatment

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：10.1007/s10549-011-1612-1

    authors： Hadad S,Iwamoto T,Jordan L,Purdie C,Bray S,Baker L,Jellema G,Deharo S,Hardie DG,Pusztai L,Moulder-Thompson S,Dewar JA,Thompson AM

    更新日期：2011-08-01 00:00:00

  • CCND1 G870A polymorphism contributes to breast cancer susceptibility: a meta-analysis.

    abstract：:Cyclin D1 (CCND1), a key cell cycle regulatory protein that governs the cell cycle progression from G1 to S phase, can promote cell proliferation or induce growth arrest and apoptosis. Since the identification of a well-characterized functional polymorphism, G870A in exon 4 of CCND1, several molecular epidemiological ...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,meta分析

    doi：10.1007/s10549-008-0195-y

    authors： Lu C,Dong J,Ma H,Jin G,Hu Z,Peng Y,Guo X,Wang X,Shen H

    更新日期：2009-08-01 00:00:00

  • Differences in breast cancer incidence among young women aged 20-49 years by stage and tumor characteristics, age, race, and ethnicity, 2004-2013.

    abstract：PURPOSE:Younger women diagnosed with breast cancer have poorer prognoses and higher mortality compared to older women. Young black women have higher incidence rates of breast cancer and more aggressive subtypes than women of other races/ethnicities. In this study, we examined recent trends and variations in breast canc...

    journal_title：Breast cancer research and treatment

    pub_type： 历史文章,杂志文章

    doi：10.1007/s10549-018-4699-9

    authors： Shoemaker ML,White MC,Wu M,Weir HK,Romieu I

    更新日期：2018-06-01 00:00:00

  • Paraneoplastic neurological syndromes and breast cancer. Regression of paraneoplastic neurological sensorimotor neuropathy in a patient with metastatic breast cancer treated with capecitabine: a case study and mini-review of the literature.

    abstract：:Paraneoplastic neurological syndromes are a rare complication of breast cancer. Nevertheless, they may be clinically relevant leading to neurological impairment. Clinicians should be aware that these neurological disorders could even precede the diagnosis of breast cancer. Here we present the case of a female patient ...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,评审

    doi：10.1007/s10549-006-9444-0

    authors： Minisini AM,Pauletto G,Bergonzi P,Fasola G

    更新日期：2007-10-01 00:00:00

  • Complementary and alternative medicine use is associated with an increased perception of breast cancer risk and death.

    abstract：PURPOSE:Complementary and alternative medicines (CAMS) are frequently used by patients with breast cancer and their use may be related to the presence of psychosocial distress. The objective of this study is to assess the presence of anxiety and depression in breast cancer patients who use CAM and assess how they perce...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-004-3779-1

    authors： Rakovitch E,Pignol JP,Chartier C,Ezer M,Verma S,Dranitsaris G,Clemons M

    更新日期：2005-03-01 00:00:00

  • A phase II trial of weekly paclitaxel, 5-fluorouracil, and leucovorin as first-line treatment for metastatic breast cancer.

    abstract：PURPOSE:This phase II multicenter trial evaluated the efficacy and toxicity of weekly paclitaxel, 5-fluorouracil, and leucovorin administered as first-line therapy for metastatic breast cancer. PATIENTS AND METHODS:The study enrolled 155 women with pathologically confirmed and measurable metastatic adenocarcinoma of t...

    journal_title：Breast cancer research and treatment

    pub_type： 临床试验,杂志文章,多中心研究

    doi：10.1023/a:1021384318470

    authors： Loesch DM,Asmar L,Canfield VA,Parker GA,Hynes HE,Ellis PG,Ferri WA Jr,Robert NJ

    更新日期：2003-01-01 00:00:00

  • The development of a predictive model to estimate cardiotoxic risk for patients with metastatic breast cancer receiving anthracyclines.

    abstract：BACKGROUND:Cardiac toxicity from anthracyclines (ACH) can lead to therapy discontinuation, hospitalization or congestive heart failure (CHF). Since such risk may vary by patient, we developed and tested a risk-prediction tool for cardiac toxicity in metastatic breast cancer (MBC) patients receiving chemotherapy with do...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-007-9803-5

    authors： Dranitsaris G,Rayson D,Vincent M,Chang J,Gelmon K,Sandor D,Reardon G

    更新日期：2008-02-01 00:00:00

  • Secreted frizzled related protein 2 (sFRP2) decreases susceptibility to UV-induced apoptosis in primary culture of canine mammary gland tumors by NF-kappaB activation or JNK suppression.

    abstract：:Tumor formation can result from a decrease in cell death, as well as an increase in cell proliferation. In spite of the high incidence of mammary gland tumors (MGTs) in female dogs, the understanding of its etiology is still poor. Consistent with several proto-oncogenes (such as Wnt) for the mammary gland, sFRP2 is ex...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-006-9233-9

    authors： Lee JL,Chang CJ,Chueh LL,Lin CT

    更新日期：2006-11-01 00:00:00

  • The influence of angiogenesis research on management of patients with breast cancer.

    abstract：:The diagnosis and treatment of patients with breast cancer is beginning to be influenced by new ideas and discoveries emerging from the field of angiogenesis research. This field, pursued in the laboratory for more than 20 years, has in the past 5 years generated clinical applications. Some of these applications have ...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,评审

    doi：10.1007/BF00666033

    authors： Folkman J

    更新日期：1995-01-01 00:00:00

  • Investigation of elemene-induced reversal of tamoxifen resistance in MCF-7 cells through oestrogen receptor α (ERα) re-expression.

    abstract：:Endocrine therapy is an important therapeutic approach for the treatment of oestrogen receptor (ER)-positive breast cancer. However, a number of these endocrine therapies can fail when the tumour loses its ER expression during treatment. To date, few studies have explored the potential clinical significance of traditi...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-012-2263-6

    authors： Zhang B,Zhang X,Tang B,Zheng P,Zhang Y

    更新日期：2012-11-01 00:00:00

  • Antimetastatic action of the prostacyclin analogue cicaprost in experimental mammary tumors.

    abstract：:In breast cancer, the survival rate strongly depends on the number of lymph nodes involved. A drug with a specific inhibitory activity on lymph node and organ metastases would therefore be a candidate for adjuvant therapy after surgery. Prostacyclin and its stable analogues have been shown to interfere with certain st...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,评审

    doi：10.1007/BF01803791

    authors： Schneider MR,Schirner M,Lichtner RB,Graf H

    更新日期：1996-01-01 00:00:00

  • The impact of having relatives affected with breast cancer on psychological distress in women at increased risk for hereditary breast cancer.

    abstract：PURPOSE:Being at hereditary risk of breast cancer (BC) may lead to elevated levels of distress because of the impact of the BC-process in relatives. OBJECTIVE:Determine the association between psychological distress and BC in relatives. We studied: kind of kinship with the affected relative(s), degree of involvement w...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-004-2623-y

    authors： van Dooren S,Seynaeve C,Rijnsburger AJ,Duivenvoorden HJ,Essink-Bot ML,Bartels CC,Klijn JG,de Koning HJ,Tibben A

    更新日期：2005-01-01 00:00:00

  • Genetic variants in trinucleotide repeat-containing 9 (TNRC9) are associated with risk of estrogen receptor positive breast cancer in a Chinese population.

    abstract：:Trinucleotide repeat-containing 9 (TNRC9), a high mobility group chromatin-associated protein, has been implicated in breast cancer metastasis to the bone. Recently, several single nucleotide polymorphisms (SNPs) of TNRC9 were identified as novel breast cancer susceptibility loci by whole genome association studies, e...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-010-0809-z

    authors： Liang J,Chen P,Hu Z,Shen H,Wang F,Chen L,Li M,Tang J,Wang H,Shen H

    更新日期：2010-11-01 00:00:00

  • Differential gene expression profile in breast cancer-derived stromal fibroblasts.

    abstract：BACKGROUND:Breast cancer is characterized by malignant transformation of epithelial cells, but stromal cells also play an important role in tumorigenesis. While tumor-derived fibroblasts display unique phenotypic properties, it is unclear whether they also represent are a specific subpopulation. MATERIALS AND METHODS:...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-007-9725-2

    authors： Singer CF,Gschwantler-Kaulich D,Fink-Retter A,Haas C,Hudelist G,Czerwenka K,Kubista E

    更新日期：2008-07-01 00:00:00